{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+and%2For+Refractory+B-cell+Lymphoma",
    "query": {
      "condition": "Relapsed and/or Refractory B-cell Lymphoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 733,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+and%2For+Refractory+B-cell+Lymphoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T13:12:46.655Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02258555",
      "title": "Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "GS-9901",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2015-01",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-10-19",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Fresno, California • Whittier, California + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Southington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258555"
    },
    {
      "nct_id": "NCT01429025",
      "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory/Relapsed Indolent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bendamustine",
          "type": "DRUG"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2012-05",
      "completion_date": "2019-07-01",
      "has_results": false,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 17,
      "location_summary": "Clive, Iowa • Des Moines, Iowa • Sioux City, Iowa + 3 more",
      "locations": [
        {
          "city": "Clive",
          "state": "Iowa"
        },
        {
          "city": "Clive",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01429025"
    },
    {
      "nct_id": "NCT04049383",
      "title": "CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia, in Relapse",
        "Acute Lymphoblastic Leukemia With Failed Remission",
        "Acute Lymphoblastic Leukemia Recurrent",
        "Acute Lymphoblastic Leukemia Not Having Achieved Remission",
        "Acute Lymphoblastic Leukemia, Pediatric",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CAR-20/19-T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "1 Year to 70 Years"
      },
      "enrollment_count": 5,
      "start_date": "2020-10-16",
      "completion_date": "2025-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04049383"
    },
    {
      "nct_id": "NCT00499239",
      "title": "A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "GS-9219",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-07",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2014-02-04",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499239"
    },
    {
      "nct_id": "NCT00313079",
      "title": "Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Lymphocytic",
        "Leukemia",
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "MAb 216",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Steven E. Coutre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2006-05",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-03",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00313079"
    },
    {
      "nct_id": "NCT02997761",
      "title": "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult B Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2017-06-27",
      "completion_date": "2025-07-17",
      "has_results": true,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Sacramento, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02997761"
    },
    {
      "nct_id": "NCT03045328",
      "title": "Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Steven E. Coutre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-09-26",
      "completion_date": "2021-08-05",
      "has_results": true,
      "last_update_posted_date": "2021-09-29",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Stanford, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03045328"
    },
    {
      "nct_id": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Hairy Cell Leukemia",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Mucosa-Associated Lymphoid Tissue Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Hairy Cell Leukemia",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oral Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Joseph Tuscano",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2020-10-23",
      "completion_date": "2025-02-21",
      "has_results": false,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04578600"
    },
    {
      "nct_id": "NCT00337168",
      "title": "S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "clofarabine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2006-10",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2015-03-25",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 91,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Orange, California + 54 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00337168"
    },
    {
      "nct_id": "NCT00669318",
      "title": "Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pentostatin",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2008-07",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-01",
      "last_synced_at": "2026-07-24T13:12:46.655Z",
      "location_count": 3,
      "location_summary": "Iowa City, Iowa • Rochester, Minnesota • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669318"
    }
  ]
}